Rallybio Corporation (RLYB)
Rallybio Statistics
Share Statistics
Rallybio has 41.61M shares outstanding. The number of shares has increased by 0.39% in one year.
| Shares Outstanding | 41.61M |
| Shares Change (YoY) | 0.39% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 72.72% |
| Shares Floating | 20.64M |
| Failed to Deliver (FTD) Shares | 80 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 337.53K, so 0.81% of the outstanding shares have been sold short.
| Short Interest | 337.53K |
| Short % of Shares Out | 0.81% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 5.61 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is -0.27. Rallybio's PEG ratio is 0.03.
| PE Ratio | -0.72 |
| Forward PE | -0.27 |
| PS Ratio | 65.73 |
| Forward PS | 0 |
| PB Ratio | 0.68 |
| P/FCF Ratio | -0.85 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rallybio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.87, with a Debt / Equity ratio of 0.
| Current Ratio | 10.87 |
| Quick Ratio | 10.87 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $25.44K |
| Profits Per Employee | $-2.31M |
| Employee Count | 25 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.56% in the last 52 weeks. The beta is -1.35, so Rallybio's price volatility has been lower than the market average.
| Beta | -1.35 |
| 52-Week Price Change | -85.56% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 23.71 |
| Average Volume (20 Days) | 99.19K |
Income Statement
In the last 12 months, Rallybio had revenue of 636K and earned -57.77M in profits. Earnings per share was -1.33.
| Revenue | 636K |
| Gross Profit | 636K |
| Operating Income | -60.5M |
| Net Income | -57.77M |
| EBITDA | -60.5M |
| EBIT | -60.5M |
| Earnings Per Share (EPS) | -1.33 |
Balance Sheet
The company has 13.9M in cash and 154K in debt, giving a net cash position of 13.75M.
| Cash & Cash Equivalents | 13.9M |
| Total Debt | 154K |
| Net Cash | 13.75M |
| Retained Earnings | -293.02M |
| Total Assets | 68.11M |
| Working Capital | 61.6M |
Cash Flow
In the last 12 months, operating cash flow was -49.28M and capital expenditures 0, giving a free cash flow of -49.28M.
| Operating Cash Flow | -49.28M |
| Capital Expenditures | 0 |
| Free Cash Flow | -49.28M |
| FCF Per Share | -1.13 |
Margins
Gross margin is 100%, with operating and profit margins of -9511.95% and -9084.12%.
| Gross Margin | 100% |
| Operating Margin | -9511.95% |
| Pretax Margin | -9084.12% |
| Profit Margin | -9084.12% |
| EBITDA Margin | -9511.95% |
| EBIT Margin | -9511.95% |
| FCF Margin | -7748.74% |
Dividends & Yields
RLYB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RLYB is $11.5, which is 4323.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $11.5 |
| Price Target Difference | 4323.1% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -6.89 |
| Piotroski F-Score | 4 |